Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-08-19
    E.g., 2018-08-19

Archive Search

4 results
12:00 AM, Feb 17, 2014  |  BC Week In Review | Clinical News  |  Clinical Results

BA058-transdermal: Phase II data

Radius Health Inc. , Cambridge, Mass.   Teijin Pharma Ltd. , Tokyo, Japan   Product: BA058-transdermal (BA058-TD
abaloparatide TD)   Business: Musculoskeletal   Molecular target: Parathyroid hormone (PTH) receptor   Description: Transdermal formulation of …
12:00 AM, Mar 18, 2013  |  BC Week In Review | Clinical News  |  Clinical Status

BA058-SC: Completed Phase III enrollment

placebo-controlled, international Phase III trial comparing 80 µg BA058-SC daily vs. 20 µg teriparatide daily. BA058-TD
12:00 AM, Jan 14, 2013  |  BC Week In Review | Clinical News  |  Clinical Status

BA058-transdermal: Completed Phase II enrollment

osteoporosis in a double-blind, placebo-controlled, international Phase II trial comparing 50, 100 and 150 µg BA058-TD
Dec. 19, 2005). Under a June 2009 deal, 3M is responsible for manufacturing and supplying BA058-TD
Teijin Pharma Ltd. , Tokyo, Japan   3M Co. (NYSE:MMM), St. Paul, Minn.   Product: BA058-transdermal (BA058-TD
12:00 AM, Oct 08, 2012  |  BC Week In Review | Clinical News  |  Clinical Status

BA058-transdermal: Phase II started

a double-blind, placebo-controlled, international Phase II trial to compare once-daily 50, 100 and 150 µg BA058-TD
Dec. 19, 2005). Under a June 2009 deal, 3M is responsible for manufacturing and supplying BA058-TD
Teijin Pharma Ltd. , Tokyo, Japan   3M Co. (NYSE:MMM), St. Paul, Minn.   Product: BA058-transdermal (BA058-TD